Renal Cancer Cell Metastasis Into the Pancreas

Wente, Moritz N.; Kleeff, Jörg; Espósito, Irene; Hartel, Mark; Müller, Michael; Fröhlich, Boris; Büchler, Markus W.; Friess, Helmut

doi:10.1097/01.mpa.0000153337.58105.47

Cited by 143 publications

(51 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is interesting to note that a literature review by Wente et al found there to be a slight predilection for pancreatic metastasis from a left kidney primary (58%), although this left-sided predilection is not supported in all series. 11 Metastasectomy at the time of nephrectomy provides a survival benefit over nephrectomy alone for patients found to have synchronous, solitary metastatic lesions.31,35 Surgical options for pancreatic metastasis must be carefully planned and individualized to each patient. Resection must aim to achieve clear margins, while leaving as much healthy pancreatic parenchyma as possible.…”

mentioning

confidence: 99%

Metastatic Disease to the Pancreas and Spleen

Showalter

Hager

Yeo

2008

Seminars in Oncology

View full text Add to dashboard Cite

mentioning

confidence: 99%

Metastatic Disease to the Pancreas and Spleen

Showalter

Hager

Yeo

2008

Seminars in Oncology

View full text Add to dashboard Cite

“…[7] The longest period between the primary cancer and the development of pancreatic metastasis was 15-22 years. [5,8] In the present study, the longest period was 27 years. Wente et al, suggest that the follow-up period in patients with early-stage RCC should extend beyond 20 years for the detection of recurrence or metastatic disease.…”

Section: Discussionmentioning

confidence: 99%

“…Wente et al, suggest that the follow-up period in patients with early-stage RCC should extend beyond 20 years for the detection of recurrence or metastatic disease. [8] The current approaches to the treatment of metastatic RCC include immunotherapy with interferon-α, targeted therapy, or one of these therapies combined with metastatectomy. Motzer et al, reported that the median progression-free survival with interferon-α was 5 months and the response rate was 6%.…”

Section: Discussionmentioning

confidence: 99%

The role of surgery in renal cell carcinoma with pancreatic metastasis

Chang¹,

Liaw²,

Chuang³

2015

Biomed J

View full text Add to dashboard Cite

Metastasis of renal cell carcinoma to the pancreas is uncommon and, in most cases, presents as a single pancreatic mass that shows a more favorable prognosis than primary pancreatic tumors. We examined patients with renal cell carcinoma metastatic to the pancreas, and discuss the clinical findings, treatment administered, and final outcomes. The present study is a retrospective analysis of renal cell carcinoma patients with pancreatic metastasis. Pancreatic tumor specimens were obtained by surgical excision, surgical biopsy, fine-needle biopsy, or endoscopic ultrasound biopsy. The surgical approaches included distal splenopancreatectomy, total pancreatectomy, or distal pancreatectomy. The physician determined the postoperative treatment regimen with interferon-α or targeted therapy on the basis of patient's performance. A total of six patients with median age of 50 years were included in the study. The median time from the primary nephrectomy to the development of pancreatic metastasis was 16 years. In the biopsy-only group, the mean stable disease period was 16.5 months. In the patients treated with surgery combined with interferon-α or targeted therapy, the mean stable disease period was 29.5 months. The patients treated with repeat mastectomy showed a mean stable disease period of 33.3 months. Aggressive surgical management is more effective than observation or immunotherapy. Recent advances in the design of targeted therapies may provide alternative treatment strategies. Combination therapy may play an important role in the future. Considering patient compliance and cost-effectiveness, resection of pancreatic metastasis is currently the first choice of treatment. (Biomed J 2015;38:173-176)

show abstract

“…According to literature data, left renal tumors result more often pancreatic metastases. [9] The already developed metastases are slow-growing, and if they are resectable, the 5-year survival rate is more than 50%. [3] In non-small cell lung cancer, pancreas metastasis is more commonly a part of multi-organ metastases.…”

Section: Discussionmentioning

confidence: 99%

Secondary tumors of the pancreas: four cases and literature review

Puskás

Henits

Kovács

2015

JBGC

View full text Add to dashboard Cite

Four cases affected by pancreatic metastases revealed by CT and MR during the last two years are presented. In Case 1 and 2 the metastatic disease appeared more than 10 years after the primary renal neoplasm was diagnosed. In the remaining two cases -non small cell lung cancer and non-Hodgkin disease -the metastases developed shortly after the onset of the primary malignancy. A literature review is given. Metastases in the pancreas are rare. The symptoms and imaging features are variable, therefore non-invasive imaging diagnosis is difficult. To resolve this problem a thorough scrutiny of the patients' medical history, and the functional imaging methods can be helpful.

show abstract

Renal Cancer Cell Metastasis Into the Pancreas

Cited by 143 publications

References 23 publications

Metastatic Disease to the Pancreas and Spleen

Metastatic Disease to the Pancreas and Spleen

The role of surgery in renal cell carcinoma with pancreatic metastasis

Secondary tumors of the pancreas: four cases and literature review

Contact Info

Product

Resources

About